Allopurinol Milpharm 300mg Tablets

Nchi: Uingereza

Lugha: Kiingereza

Chanzo: myHealthbox

Viambatanisho vya kazi:

Allopurinol

Inapatikana kutoka:

Milpharm Limited

ATC kanuni:

M04AA01

INN (Jina la Kimataifa):

Allopurinol

Kipimo:

300mg

Dawa fomu:

Tablets

Njia ya uendeshaji:

Oral use

Vitengo katika mfuko:

1000, 500, 100, 84, 70, 56, 42, 28, 21, 15 and 14 tablets.

Dawa ya aina:

POM - Prescription Only Medicine

Viwandani na:

Milpharm Limited

Kundi la matibabu:

Preparations inhibiting uric acid production

Matibabu dalili:

It is indicated for reducing urate/uric acid formation in conditions where urate/uric acid deposition has already occurred (e.g. gouty arthritis, skin tophi, nephrolithiasis) or is a predictable clinical risk (e.g. treatment of malignancy potentially leading to acute uric acid nephropathy). The main clinical conditions where urate/uric acid deposition may occur are: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously, or after cytotoxic therapy; certain enzyme disorders which lead to overproduction of urate, for example: hypoxanthine-guanine phosphoribosyltransferase, including Lesch-Nyhan syndrome; glucose-6-phosphatase including glycogen storage disease; phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidotransferase; adenine phosphoribosyltransferase. Allopurinol is indicated for management of 2,8-dihydroxyadenine (2,8-DHA) renal stones r

Idhini hali ya:

Authorised

Idhini ya tarehe:

2009-03-02

Taarifa za kipeperushi

PACKAGE LEAFLET: INFORMATION FOR THE USER
ALLOPURINOL TABLETS BP 300MG
(allopurinol)
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE.
·
Keep this leaflet. You may need to read it again.
·
If you have any further questions, ask your doctor or pharmacist.
·
This medicine has been prescribed for you. Do not pass it on to
others. It may harm 
them, even if their symptoms are the same as yours.
·
If any of the side effects gets serious, or if you notice any side
effects not listed in this 
leaflet, please tell your doctor or pharmacist.
IN THIS LEAFLET:
1.
What allopurinol Tablets are and what they are used for
2.
Before you take Allopurinol Tablets
3.
How to take Allopurinol Tablets
4.
Possible side effects
5.
How to store Allopurinol Tablets
6.  
Further information
Allopurinol Tablets belong to a group of medicines called enzyme
inhibitors. Allopurinol Tablets 
are used in:
·
long term prevention of gout
·
prevention of kidney stones
·
treatment of high levels of uric acid associated with tumors and their
treatment
·
certain enzyme disorder in particular Lesch Nyhan syndrome
Serious skin rashes (Hypersensitivity syndrome, Stevens- Johnson
syndrome, toxic epidermal 
necrolysis) have been reported with the use of allopurinol.
Frequently, the rash can involve 
ulcers of the mouth, throat, nose, genitals and conjunctivitis (red
and swollen eyes). These 
serious skin rashes are often preceded by influenza-like symptoms
fever, headache, body 
ache (flu-like symptoms). The rash may progress to widespread
blistering and peeling of the 
skin.
These serious skin reactions can be more common in people of Han
Chinese or Thai origin.
If you develop a rash or these skin symptoms, stop taking allopurinol
and contact your doctor 
immediately.
DO NOT TAKE ALLOPURINOL TABLETS IF:
·
you are sensitive or allergic to Allopurinol or any of the
ingredients in the tablets (listed 
in section 6).
Do not take Allopurinol Tablets if the above applies to you. If you
are not su

Tabia za bidhaa

Allopurinol Milpharm 300mg Tablets
Summary of Product Characteristics Updated 24­Aug­2015 | Aurobindo Pharma ­ Milpharm Ltd.
1. Name of the medicinal product
Allopurinol Tablets BP 300mg
2. Qualitative and quantitative composition
Each tablet contains 300 mg Allopurinol.
For a full list of excipients, see section 6.1.
3. Pharmaceutical form
Tablets.
White, round tablets, with convex sides with emboss MAL 300 on one side and plain on the reverse.
4. Clinical particulars
4.1 Therapeutic indications
Allopurinol is indicated for reducing urate/uric acid formation in conditions where urate/uric acid deposition has already
occurred (e.g. gouty arthritis, skin tophi, nephrolithiasis) or is a predictable clinical risk (e.g. treatment of malignancy
potentially leading to acute uric acid nephropathy). The main clinical conditions where urate/uric acid deposition may
occur are: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative
disease with high cell turnover rates, in which high urate levels occur either spontaneously, or after cytotoxic therapy;
certain enzyme disorders which lead to overproduction of urate, for example: hypoxanthine­guanine
phosphoribosyltransferase, including Lesch­Nyhan syndrome; glucose­6­phosphatase including glycogen storage
disease; phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidotransferase; adenine
phosphoribosyltransferase. Allopurinol is indicated for management of 2,8­dihydroxyadenine (2,8­DHA) renal stones
related to deficient activity of adenine phosphoribosyltransferase.
Allopurinol is indicated for the management of recurrent mixed calcium oxalate renal stones in the presence of
hyperuricosuria, when fluid, dietary and similar measures have failed.
4.2 Posology and method of administration